Establishment Labs (NASDAQ:ESTA) Trading Down 6.7%

Establishment Labs Holdings Inc. (NASDAQ:ESTA)’s share price was down 6.7% during trading on Wednesday . The company traded as low as $49.18 and last traded at $50.33. Approximately 130,512 shares were traded during trading, a decline of 68% from the average daily volume of 402,328 shares. The stock had previously closed at $53.94.

Analyst Ratings Changes

A number of research analysts recently commented on ESTA shares. Mizuho raised their price target on Establishment Labs from $50.00 to $65.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. JPMorgan Chase & Co. lifted their price objective on shares of Establishment Labs from $46.00 to $53.00 and gave the company an “overweight” rating in a research note on Thursday, February 29th. Stephens reaffirmed an “overweight” rating and issued a $47.00 target price on shares of Establishment Labs in a report on Thursday, January 11th. Finally, Citigroup boosted their price target on Establishment Labs from $49.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Establishment Labs presently has a consensus rating of “Buy” and a consensus target price of $55.00.

Establishment Labs Stock Performance

The company has a market capitalization of $1.56 billion, a price-to-earnings ratio of -18.69 and a beta of 1.23. The company has a quick ratio of 1.67, a current ratio of 3.06 and a debt-to-equity ratio of 10.26. The stock has a 50 day moving average of $50.50 and a 200 day moving average of $37.52.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Wednesday, May 8th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.07. Establishment Labs had a negative net margin of 47.53% and a negative return on equity of 357.81%. The business had revenue of $37.17 million for the quarter, compared to analyst estimates of $35.61 million. During the same quarter in the previous year, the business earned ($0.48) earnings per share. Establishment Labs’s revenue for the quarter was down 20.1% on a year-over-year basis. As a group, analysts predict that Establishment Labs Holdings Inc. will post -1.63 EPS for the current year.

Hedge Funds Weigh In On Establishment Labs

Institutional investors and hedge funds have recently modified their holdings of the company. Baker Avenue Asset Management LP bought a new stake in shares of Establishment Labs during the 3rd quarter valued at about $59,000. Clear Street Markets LLC bought a new stake in Establishment Labs during the 3rd quarter valued at approximately $88,000. FNY Investment Advisers LLC bought a new position in Establishment Labs in the 4th quarter worth approximately $93,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Establishment Labs by 67.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,591 shares of the company’s stock valued at $119,000 after buying an additional 1,845 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Establishment Labs during the fourth quarter valued at approximately $120,000. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.